Review Article Forensic Medicine Health Policy Nuclear Medicine
Rethinking ventilator-free days in patients on haemodialysis: the role of continuous glucose monitoring

Rethinking ventilator-free days in patients on haemodialysis: the role of continuous glucose monitoring

Authors

Lucas Novak

Lucas Novak

Aga Khan University Hospital, Guernsey

Corresponding
Mei Osei

Mei Osei

King Fahad Medical City, Argentina

Daniel Moreau

Daniel Moreau

Hamad Medical Corporation, Qatar

Published

November 28, 2023

Paper ID

PAP-000269

Status

Published

DOI

10.65712/tmj.test000527

Rethinking ventilator-free days in patients on haemodialysis: the role of continuous glucose monitoring

Advance Services

Create Content

Video • Presentation • Poster

From $97.00 per format

Abstract

Background: Earlier studies of continuous glucose monitoring were small or single-centre. Methods: Missing data were handled with multiple imputation. Results: ventilator-free days occurred in 5% of the intervention group versus 25% of controls. Serious adverse events were rare and similar between groups. Conclusion: Strengths include the sample size and blinded outcome assessment.

Introduction

Earlier studies of continuous glucose monitoring were small or single-centre. Practice around continuous glucose monitoring varies widely between centres. The cost of ventilator-free days to health systems is substantial.

Earlier studies of continuous glucose monitoring were small or single-centre. Guidelines make only a weak recommendation on continuous glucose monitoring. ventilator-free days remains a leading cause of avoidable harm among patients on haemodialysis.

Materials and Methods

We conducted a randomised controlled trial across 3 centres between 2017 and 2023. We conducted a randomised controlled trial across 6 centres between 2018 and 2022.

Missing data were handled with multiple imputation. Eligible participants were patients on haemodialysis. The primary outcome was ventilator-free days, assessed blind to allocation.

We conducted a randomised controlled trial across 9 centres between 2014 and 2022. Missing data were handled with multiple imputation. Eligible participants were patients on haemodialysis.

Missing data were handled with multiple imputation. We conducted a randomised controlled trial across 10 centres between 2014 and 2021. Eligible participants were patients on haemodialysis.

Results

Serious adverse events were rare and similar between groups. Effects were consistent across prespecified subgroups. ventilator-free days occurred in 10% of the intervention group versus 22% of controls. ventilator-free days occurred in 22% of the intervention group versus 14% of controls.

The adjusted odds ratio was 0.70 (95% CI 0.21 to 0.72). The adjusted odds ratio was 0.60 (95% CI 0.41 to 0.80).

Serious adverse events were rare and similar between groups. ventilator-free days occurred in 9% of the intervention group versus 27% of controls. 861 participants were included (median age 44 years).

GroupnEvents
Female82359
Male38678
Intervention22557
Age < 658512
Male22573
TABLE 1: Secondary outcomes
Values are n (%) unless stated otherwise.
Figure 1
FIGURE 1: Trend in ventilator-free days
Shown for patients on haemodialysis; error bars are 95% confidence intervals.
Figure 2
FIGURE 2: Kaplan–Meier curve for ventilator-free days
Shown for patients on haemodialysis; error bars are 95% confidence intervals.

Effects were consistent across prespecified subgroups. ventilator-free days occurred in 11% of the intervention group versus 21% of controls. ventilator-free days occurred in 5% of the intervention group versus 26% of controls.

Effects were consistent across prespecified subgroups. ventilator-free days occurred in 4% of the intervention group versus 26% of controls. Serious adverse events were rare and similar between groups.

Discussion

These findings suggest that continuous glucose monitoring is associated with better ventilator-free days in patients on haemodialysis. Strengths include the sample size and blinded outcome assessment.

Strengths include the sample size and blinded outcome assessment. Residual confounding cannot be excluded.

Conclusions

Continuous glucose monitoring is a reasonable option for patients on haemodialysis to improve ventilator-free days.

References

1. Novak F, Lindqvist H, et al. Delayed cord clamping and surgical site infection. N Engl J Med. 2014;85(4):312-1020.

2. Okafor Z, Rahman W, et al. Machine-learning triage and patient satisfaction. BMJ. 2008;106(9):748-1145.

3. Osei L, Farouk H, et al. Machine-learning triage and in-hospital mortality. Pediatrics. 2011;100(8):637-1074.

4. Okafor B, Ibrahim B, et al. Pharmacist-led medication review and post-operative delirium. Ann Intern Med. 2014;343(3):97-1078.

5. Farouk G, Zhang W, et al. Early mobilisation and falls. N Engl J Med. 2009;27(4):842-1346.

6. Farouk W, Moreau G, et al. High-flow nasal oxygen and glycaemic control. JAMA. 2010;217(5):494-1190.

7. Ahmed Z, Costa M, et al. Vitamin D supplementation and 30-day readmission. Ann Intern Med. 2010;365(1):374-1409.

8. Nasser B, Kaur Q, et al. Point-of-care ultrasound and health-related quality of life. Pediatrics. 2022;253(1):125-1518.

Appendices

Supplementary tables are available on request.